Adjusted estimate of the prevalence of hepatitis delta virus in 25 countries and territories

Devin M. Razavi-Shearer,Maria Buti,Frank Tacke,Norah A. Terrault,Stefan Zeuzem,Zaigham Abbas,Alessio Aghemo, Ulus S. Akarca, Nasser M. Al Masri,Abduljaleel M. Alalwan,Marianne Alanko Blome,Soo Aleman, Abdullah S. Alghamdi, Mohammed Alghamdi, Saad Alghamdi,Waleed K. Al-Hamoudi, Ela Ali,Abdulrahman A. Aljumah,Ibrahim H. Altraif, Jazag Amarsanaa,Tarik Asselah,Oidov Baatarkhuu,Adriana Babameto,Ziv Ben-Ari,Thomas Berg,Mia J. Biondi, Wornei S. M. Braga, Carlos E. Brandao-Mello,Robert S. Brown,Maurizia R. Brunetto,Joaquin Cabezas, Mariana Cardoso,Henry Lik Yuen Chan,Hugo Cheinquer,Chien-Jen Chen,Pei-Jer Chen,Cheng-Hung Chien, Hailey Child,Wan-Long Chuang, Laura E. Cisneros Garza,Barbara Coco,Carla S. Coffin,Nicola Coppola, Markus Cornberg,Antonio Craxi,Javier Crespo, Liri Cuko,Victor De Ledinghen,Ann-Sofi Duberg,Ohad Etzion,Maria Lucia G. Ferraz, Paulo R. A. Ferreira,Xavier Forns,Graham R. Foster,James Fung,Giovanni B. Gaeta,Javier Garcia-Samaniego, Jordan Genov,Liliana S. Gheorghe,Pierre M. Gholam,Robert G. Gish,Jeffrey Glenn,Adrian Goldis,Saeed S. Hamid,Julian Hercun,Yao-Chun Hsu,Ching-Chih Hu,Jee-Fu Huang,Ramazan Idilman,Wasim S. M. Jafri, Naveed Janjua, Deian Jelev, Anna Jerkeman,Jidong Jia,Martin Kaberg,Kelly D. E. Kaita,Jia-Horng Kao,Aamir G. Khan,Do Young Kim,Loreta A. Kondili,Martin Lagging,Pietro Lampertico,Pablo Lazaro,Jeffrey Lazarus,Mei-Hsuan Lee,Young-Suk Lim, Cirley M. O. Lobato,Guilherme Macedo, Rui T. Marinho,Paul J. Marotta, Alexanda Martins,Maria Cassia Mendes-Correa,Nahum Mendez-Sanchez,Maria-Cristina Navas,Qing Ning,Necati Ormeci,Mauricio Orrego,Carla Osiowy,Calvin Q. Pan,Mario G. Pessoa, Zahra Z. Piracha, Cora Pop, Jose A. Presa Ramos,Huma Qureshi,Giovanni Raimondo,Alnoor Ramji, Kathryn Razavi-Shearer, Sofia Ribeiro, Cielo Y. Rios-Hincapie,Manuel Rodriguez,William M. C. Rosenberg,Dominique Roulot, Stephen D. Ryder,Umar Saeed,Rifaat Safadi,Faisal M. Sanai, Juan F. Sanchez-Avila,Teresa A. Santantonio,Christoph Sarrazin,Wai-Kay Seto,Daniel Shouval,Marieta Y. Simonova,Junko Tanaka, Tammo L. Tergast, Oyunsuren Tsendsuren,Cristina Valente,Juan Miguel Villalobos-Salcedo, Alexis S. Voeller,Yasir Waheed,Grace L-H Wong,Vincent W-S Wong,Jaw-Ching Wu, Hwai- Yang,Terry C-F Yip,Ming-Lung Yu,Man-Fung Yuen, Cihan Yurdaydin,Eli Zuckerman, Homie A. Razavi

JOURNAL OF HEPATOLOGY(2024)

引用 0|浏览9
暂无评分
摘要
Background & Aims: Hepatitis delta virus (HDV) is a satellite RNA virus that requires the hepatitis B virus (HBV) for assembly and propagation. Individuals infected with HDV progress to advanced liver disease faster than HBV-monoinfected individuals. Recent studies have estimated the global prevalence of anti-HDV antibodies among the HBV-infected population to be 5-15%. This study aimed to better understand HDV prevalence at the population level in 25 countries/territories. Methods: We conducted a literature review to determine the prevalence of anti-HDV and HDV RNA in hepatitis B surface antigen (HBsAg)-positive individuals in 25 countries/territories. Virtual meetings were held with experts from each setting to discuss the findings and collect unpublished data. Data were weighted for patient segments and regional heterogeneity to estimate the prevalence in the HBV-infected population. The findings were then combined with The Polaris Observatory HBV data to estimate the anti-HDV and HDV RNA prevalence in each country/territory at the population level. Results: After adjusting for geographical distribution, disease stage and special populations, the anti-HDV prevalence among the HBsAg+ population changed from the literature estimate in 19 countries. The highest anti-HDV prevalence was 60.1% in Mongolia. Once adjusted for the size of the HBsAg+ population and HDV RNA positivity rate, China had the highest absolute number of HDV RNA+ cases. Conclusions: We found substantially lower HDV prevalence than previously reported, as prior meta-analyses primarily focused on studies conducted in groups/regions that have a higher probability of HBV infection: tertiary care centers, specific risk groups or geographical regions. There is large uncertainty in HDV prevalence estimates. The implementation of reflex testing would improve estimates, while also allowing earlier linkage to care for HDV RNA+ individuals. The logistical and economic burden of reflex testing on the health system would be limited, as only HBsAg+ cases would be screened.
更多
查看译文
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要